Unique platform engineered to trigger pro-resolution responses, restoring immune homeostasis in inflammatory disorders without broad immunosuppression.
CAMBRIDGE, Mass., Jan. 22, 2026 — Resolve M Therapeutics, Inc., a biotech focused on developing the world’s first all-encompassing pro-resolution platform for target ID, validation, and drug discovery to treat inflammatory diseases, has revealed it is emerging from stealth mode. Resolve M was established via a strategic partnership between Johnson & Johnson—through its corporate venture capital arm, Johnson & Johnson Innovation – JJDC, Inc.—and General Inception, a global biotech company accelerator, and underscores a strong dedication to early-stage biotech innovation.
Drawing on distinct insights and expertise from Professor Nir Hacohen’s lab at the Broad Institute, Resolve M’s innovative platform seeks to unlock the pro-resolving potential of the MS1 (myeloid state 1) cell to reestablish homeostasis in patients with chronic inflammatory and autoimmune conditions, without fully suppressing the immune system. This method offers a potentially safer and more effective therapeutic alternative than existing options. Pro-resolving mechanisms restore tissues to homeostasis after infection or injury during the resolution phase of inflammation.
Professor Nir Hacohen, core member of the Broad Institute and professor of medicine at Harvard Medical School said: “Our findings of a defined myeloid cell state with suppressive functions provides a platform for induction, or modulation, of immune cells and their functions for therapeutic purposes in diverse inflammatory conditions.”
Activating pro-resolving pathways has long been an area of active research due to their transformative potential. However, prior efforts in this field have centered mainly on resolving lipid mediators, which have not met clinical expectations. Johnson & Johnson Innovation – JJDC Inc. and General Inception have recognized the promise of Professor Hacohen’s platform to generate pro-resolving cells in vivo and in vitro, facilitating mechanistic understanding of myeloid cell function. By utilizing JJDC’s approach to building early-stage companies, General Inception will be better equipped to transition from Professor Hacohen’s groundbreaking science to clinical proof of concept.
Venkat Reddy, CSO of General Inception, commented: “By targeting the body’s innate resolution mechanisms with translatable biomarkers, we can rapidly validate our approach in patients and make real-time adjustments. This integrated model, merging world-class science, purpose-built infrastructure, and deep operational expertise, allows us to shorten development timelines, accelerating our journey to deliver transformative treatments for patients with chronic inflammatory diseases.”
Using this highly distinct strategy, Resolve M intends to develop the world’s first all-encompassing pro-resolution platform for target identification, validation, and drug discovery targeting inflammatory diseases.
About Resolve M Therapeutics
Resolve M is a Cambridge, MA-based biotech focused on developing the world’s first comprehensive pro-resolution platform for target ID, validation, and drug discovery to treat inflammatory diseases. With a unique platform technology originating from the Broad Institute, Resolve M seeks to leverage innate immune pro-resolving responses to address inflammatory disorders without fully suppressing the immune system, offering a superior therapeutic option for chronic cases.
About General Inception
General Inception (GI) is pioneering company creation as an Igniter firm. General Inception partners with exceptional scientific founders at the start of their journey to efficiently translate their groundbreaking innovations into transformational companies that tackle humanity’s grand challenges. As a business co-founder, GI combines domain and functional expertise, executive talent, infrastructure and development resources, and capital to launch, nurture, and scale companies. GI is backed by leading venture capital firms including Genoa Ventures, Hughes Ventures, Northpond Ventures, OMX Ventures, Paladin Capital Group, and Vertical Venture Partners.
For more information, please visit .
SOURCE Resolve M Therapeutics